Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 21Terminated 4Unknown 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Cholangiocarcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Gallbladder Neoplasms 7Neoplasms 6Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5pembrolizumab 4Cyclophosphamide 4olaparib 3liposomal doxorubicin 3fludarabine 3ribociclib 2palbociclib 2mirvetuximab soravtansine 2Topotecan 2Nivolumab 2Letrozole 2Fulvestrant 2Blood Specimen Collection 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1niraparib 1lenvatinib 1isoquercitrin 1fludarabine phosphate 1durvalumab 1cemiplimab 1abemaciclib 1Tinzaparin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1SLC25A33 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Ovarian Epithelial × Gemcitabine × Clear all
NCT04516447 2026-04-07

MUIR

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1 Recruiting
172 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡